EUVIMEDEUVIMED entdecken
Open Access

LC‐HRMS‐Based Metabolic Profiling of the REV‐ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti‐Doping Analysis

Ansar Babu Palathinkal iD, S Farook Basha iD, Saraswathy Laya iD, Jahfar Nalakath iD, O K Praseen iD, Marina Joseph, Shantymol V Jose

Rapid Communications in Mass Spectrometry · 2026

DOI: 10.1002/rcm.70149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2026. Verfasst von Ansar Babu Palathinkal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Camel Forensic Laboratory, Central Veterinary Research Laboratory, Dubai, UAE. Hauptthemen laut MEDLINE: Liver, Cunninghamella, Thiophenes, Pyrrolidines. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

SR9009 is a synthetic REV‐ERB agonist with potential performance‐enhancing properties and is included on the World Anti‐Doping Agency (WADA) Prohibited List for human sport. Its potential misuse has also raised concerns in animal sports, particularly equine and camel racing. Although SR9009 metabolism has been investigated in human and equine models, its metabolic fate in racing camels ( Camelus dromedarius ) remains unclear. Characterizing its biotransformation pathways and identifying suitable biomarkers are essential for developing reliable anti‐doping screening strategies for camel racing.

Methods

An in vitro metabolic study was conducted using camel liver homogenate and the fungal model Cunninghamella elegans . Metabolites were characterized using liquid chromatography‐high‐resolution mass spectrometry (LC‐HRMS). Putative structural elucidation was achieved through accurate mass measurements of precursor and product ions. Diagnostic fragmentation pathways were established using collision‐induced dissociation (CID) tandem mass spectrometry (MS/MS), enabling the systematic identification of metabolic modifications based on characteristic fragment ions and neutral losses.

Results

Seventeen Phase I metabolites of SR9009 were identified. Major biotransformation pathways included N‐dealkylation, mono‐hydroxylation, di‐hydroxylation, and combinations thereof. The N‐dealkylated metabolite was the predominant metabolite detected in both camel liver homogenate and Cunninghamella elegans , indicating its suitability as a primary analytical target for anti‐doping screening. No Phase II metabolites were detected under the experimental conditions employed. Putative structural assignments were supported by characteristic high‐resolution tandem mass spectral fragmentation patterns.

Conclusions

This study provides the first comprehensive metabolic profile of SR9009 in a camel‐specific in vitro model. The identification of 17 Phase I metabolites, particularly the predominant N‐dealkylated derivative, provides valuable analytical targets for doping control. These findings establish a metabolic foundation for future in vivo studies to determine pharmacokinetics and detection windows in racing camels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverCunninghamellaThiophenesPyrrolidinesLiquid Chromatography-Mass SpectrometryBenzodioxolesSpiro CompoundsAnimalsCamelusDoping in SportsTandem Mass SpectrometrySubstance Abuse Detection

Stichwörter der Autor:innen

Camelus dromedariusLC‐HRMSREV‐ERB agonistSR9009doping controlin vitro metabolism

Substanzen

ThiophenesSR9009PyrrolidinesBenzodioxolesSpiro Compounds

Autor:innen und Institutionen

  • Camel Forensic Laboratory, Central Veterinary Research Laboratory, Dubai, UAE.
  • Post Graduate and Research Department of Chemistry, Jamal Mohamed College (Affiliated to Bharathidasan University), Tiruchirappal, Tamil Nadu, India.
  • Department of Chemistry, College of Science, United Arab Emirates University, Al Ain, UAE.
  • Department of Bacteriology, Diagnostic Section, Central Veterinary Research Laboratory, Dubai, UAE.

ORCID-Profile: Ansar Babu Palathinkal, S Farook Basha, Saraswathy Laya, Jahfar Nalakath, O K Praseen

Zitieren

APA

Palathinkal, A. B., Farook Basha, S., Laya, S., Nalakath, J., Praseen, O. K., Joseph, M., & Jose, S. V. (2026). LC‐HRMS‐Based Metabolic Profiling of the REV‐ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti‐Doping Analysis. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.70149

Vancouver

Palathinkal AB, Farook Basha S, Laya S, Nalakath J, Praseen OK, Joseph M, et al. LC‐HRMS‐Based Metabolic Profiling of the REV‐ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti‐Doping Analysis. Rapid Communications in Mass Spectrometry. 2026. doi:10.1002/rcm.70149

BibTeX
@article{Palathinkal2026,
  author = {Palathinkal, Ansar Babu and Farook Basha, S and Laya, Saraswathy and Nalakath, Jahfar and Praseen, O K and Joseph, Marina and Jose, Shantymol V},
  title = {LC‐HRMS‐Based Metabolic Profiling of the REV‐ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti‐Doping Analysis},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2026},
  doi = {10.1002/rcm.70149}
}
Kostenlos starten →